Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C5H11NO2S.ClH |
Molecular Weight | 185.672 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)[C@@H](N)CS
InChI
InChIKey=JFKJWWJOCJHMGV-WCCKRBBISA-N
InChI=1S/C5H11NO2S.ClH/c1-2-8-5(7)4(6)3-9;/h4,9H,2-3,6H2,1H3;1H/t4-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23892097Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/ethyl-l-cysteine-hydrochloride.html | https://www.ncbi.nlm.nih.gov/pubmed/16309906 | https://www.ncbi.nlm.nih.gov/pubmed/15203134
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23892097
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/ethyl-l-cysteine-hydrochloride.html | https://www.ncbi.nlm.nih.gov/pubmed/16309906 | https://www.ncbi.nlm.nih.gov/pubmed/15203134
Ethyl cysteinate is derivative of semi-essential proteinogenic amino acid Cysteine. Ethyl cysteinate is widely used in food additive, cosmetic, pharmaceutical area. Ethyl cysteinate is membrane-permeable, readily enters peripheral tissues and the brain, and increases intracellular pools of cysteine in these tissues via a membrane-associated carboxylesterase. The increased availability of cysteine directly alters the redox status of cells and enhances glutathione production. The enhanced biovailability of L-cysteine and L-glutathione would also promote the direct formation of the S-nitrosothiols, L-S-nitrosocysteine and L-S-nitrosoglutathione and the overall S-nitrosylation status of functional proteins in cells.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: membrane-associated carboxylesterase Sources: https://www.ncbi.nlm.nih.gov/pubmed/8216362 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15203134
The antiinflammatory activity of Ethyl cysteinate was assessed from it’s ability to inhibit the paw edema induced by carrageenan in Balb/C mice. The Ethyl cysteinate were administered ip at a dose of 150 lmol/kg and demonstrated a significant inhibition of the edema.
The gastrointestinal toxicity profile of Ethyl cysteinate (84 mkM/kg) was evaluated in vivo following a 4-day oral dosage scheme in rats.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16309906
Ethyl cysteinate activity was evaluated in lipid peroxidation assay. The supernatant fraction hepatic microsomal membrane lipids. Lipid peroxidation was
assessed by the formation of thiobarbituric acid (TBA)-reactive substances (e.g. malondialdehyde). Cysteine ethyl ester (1 uM) inhibited lipid peroxidation by 49%.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB14334MIG
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL863
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | |||
|
212-779-6
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | |||
|
13358
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | |||
|
100000077082
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | |||
|
DTXSID4046527
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | |||
|
117387
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | |||
|
AM467TB2I1
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | |||
|
236634
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
868-59-7
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY | |||
|
SUB21813
Created by
admin on Fri Dec 15 19:50:14 GMT 2023 , Edited by admin on Fri Dec 15 19:50:14 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD